Dr. Hutson on Challenges With Targeted Therapy in Non-Clear Cell RCC

Video

Thomas Hutson, DO, PharmD, discusses challenges with targeted therapy in non-clear cell renal cell carcinoma.

Thomas Hutson, DO, PharmD, director, Urologic Oncology Program, co-chair, Urologic Cancer Research and Treatment Center, Baylor University Medical Center, professor of medicine, Texas A&M College of Medicine, discusses challenges with targeted therapy in non-clear cell renal cell carcinoma (RCC).

Non-clear cell RCC subtypes have individual natural histories, their own responses to various therapies, and their own genetic abnormalities, says Hutson.

 Notably, the Von Hippel-Lindau (VHL) gene, which was discovered in the 1990s, is commonly mutated. Loss of function in VHLresults in increased uptake of hypoxia-inducible factor (HIF) and downstream increase of VEGF, Hutson explains. Ultimately, the discovery of VHL led to the development of targeted therapies, such as sunitinib (Sutent), lenvatinib (Lenvima), and cabozantinib (Cabometyx) in clear cell RCC.

However, VHL mutations are not oncogenic drivers in non-clear cell RCC. Instead, non-clear cell histologies are associated with other abnormalities, such as c-MET in papillary RCC and fumarate hydratase deficiency in papillary type 2 RCC. As such, there is a significant need to develop additional targeted therapies for patients with non-clear cell RCC, Hutson concludes.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.